Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Retrospective Study Exemplifies the Environmental and Health Impacts of Decentralizing Cancer Care

August 18, 2024

Article

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials

August 16, 2024

Article

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC

August 16, 2024

Article

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Management of Emetogenicity of Antibody-Drug Conjugates

August 15, 2024

Video

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

August 15, 2024

Video

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

August 15, 2024

Video

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

August 15, 2024

Video

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care

August 15, 2024

Video

Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.

Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer

August 14, 2024

Video

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

August 13, 2024

Video

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11, 2024

Article

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment

August 09, 2024

Video

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 09, 2024

Video

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

August 08, 2024

Podcast

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 08, 2024

Video

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 08, 2024

Article

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Novel Studies Seek to Optimize HER2+ Breast Cancer Management

August 07, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 07, 2024

Video

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator

August 07, 2024

Article

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 06, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.